Effect of baseline characteristics on the efficacy of dulaglutide added to basal insulin in Chinese patients with type 2 diabetes: A subgroup analysis of AWARD‐CHN3-Reference-Cited by-同舟云学术

Effect of baseline characteristics on the efficacy of dulaglutide added to basal insulin in Chinese patients with type 2 diabetes: A subgroup analysis of AWARD‐CHN3

Published:2024-01-07 Issue:4 Volume:26 Page:1540-1543
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Tong Guoyu¹,Lu Song²,Kuang Hongyu³,Li Yan⁴,Deng Yuying⁵,Lou Ying⁵,Wang Weimin¹,Zhu Dalong¹^ORCID

Affiliation:

1. Department of Endocrinology Drum Tower Hospital Affiliated to Nanjing University School of Medicine Nanjing China

2. Chongqing General Hospital Chongqing China

3. Department of Endocrinology The First Affiliated Hospital of Harbin Medical University Harbin China

4. Department of Endocrinology and Metabolism, Sun Yat‐sen Memorial Hospital Sun Yat‐sen University Guangzhou China

5. Lilly China Drug Development and Medical Affairs Center Eli Lilly (Suzhou) Pharmaceutical Co., Ltd. Shanghai China

Funder

Eli Lilly and Company

Publisher

Wiley

Reference6 articles.

1. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022

2. Dulaglutide, a long‐acting GLP‐1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes;Jimenez‐Solem E;Curr Opin Mol Ther,2010

3. Efficacy and safety of adding once‐weekly dulaglutide to basal insulin for inadequately controlled type 2 diabetes in Chinese patients (AWARD‐CHN3): A randomized, double‐blind, placebo‐controlled, phase III trial

4. Effect of once‐weekly dulaglutide on glycated haemoglobin ( HbA1c ) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c

5. Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes